Acute Migraine Agents Prior Authorization Request Form

Member Information (required) Member Name:			F	Provider Information (required)		
			Provider Name:			
Insurance ID#:			NPI#:		Specialty:	
Date of Birth:			Office Phone:	Office Phone:		
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street A	Office Street Address:		
Phone:			City:	State	e: Zip:	
		Modication	on Information			
Medication Name:			Strength:	I (required)	Dosage Form:	
☐ Check if generic substitution is acceptable			Directions for U	leo:	Desage Fermi	
	t is for continuation	•	Directions for t	J3 C .		
			I Information (required)		
Select the diag	nosis below:					
☐ Acute treatm						
Other diagno	sis:			ICD-10 Code(s):		
	-	ent has had an inad	equate response to	-		
□ Almotriptan□ Rizatriptan□ Rizatriptan orally disintegra			musting tablet (ODT)	□ Sumatriptan tablet ng tablet (ODT) □ Zolmitriptan		
□ Eletriptan□ Frovatriptan		atriptan orally disinted natriptan injection	grating tablet (ODT)		ımıtrıptan İmitriptan ODT	
□ Naratriptan		natriptan nasal spray		4 201		
		e specify all agent(s)				
_		iests, also answer tl	•			
-	nad an inadequat			f sumatriptan a	and naproxen as separate	
Reauthorization	າ:					
	•	est, answer the follo	•			
Is there docume	ntation of positive	e clinical response to	therapy? □ Yes □	No		
Quantity limit ro		· MONTUO				
•	ntity requested pe	y a neurologist within	the nast three years	2 🗆 Vos 🗇 N	lo.	
·		rial of prophylactic			10	
☐ Beta-blocker	ilelit ilas ilau a t	ilai oi piopilylactic	☐ Calcium channel			
	ne-related peptid	e receptor	Cyproheptadine			
		or prophylaxis (e.g.	□ Topiramate			
		zumab [Ajovy] or	☐ Tricyclic antidepr	ressant		
galcanezuma	ıb [Emgality] 120ı	ng)	□ Valproic acid			
Are there any other this review?	comments, diagnos	es, symptoms, medicatio	ons tried or failed, and/or	any other inforn	nation the physician feels is important to	
Please note:	This request may be	denied unless all required	information is received			

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of the Pharmacy Benefit Manager. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: AcuteMigraineAgents_FSVF_2022Jan